The evidence base for the prescribing of aripiprazole in maintenance treatment of bipolar disorder is limited to a single trial, sponsored by the manufacturer of aripiprazole, according to a rigorous appraisal of the evidence for its use.

Source: Limitations of evidence base for prescribing aripiprazole in maintenance therapy of bipolar disorder


David Cottle

UBB Owner & Administrator